View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	May 31, 2017	Jul. 04, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	ORAMED PHARMACEUTICALS INC.
Entity Central Index Key	0001176309
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Document Type	10-Q
Document Period End Date	May 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Trading Symbol	ORMP
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		13,320,962

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	May 31, 2017	Aug. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 1,733	$ 3,907
Short-term deposits	21,400	24,254
Marketable securities	3,072	2,855
Restricted cash	16	16
Prepaid expenses and other current assets	127	198
Total current assets	26,348	31,230
LONG-TERM ASSETS:
Long-term deposits and investment	12,005	11,043
Marketable securities	1,409	530
Amounts funded in respect of employee rights upon retirement	13	11
Property and equipment, net	17	16
Total long-term assets	13,444	11,600
Total assets	39,792	42,830
CURRENT LIABILITIES:
Accounts payable and accrued expenses	2,526	1,411
Deferred revenues	2,449	2,162
Related parties	61	48
Total current liabilities	5,036	3,621
LONG-TERM LIABILITIES:
Deferred revenues	14,455	12,604
Employee rights upon retirement	18	14
Provision for uncertain tax position	11	11
Other liabilities	462	390
Total long-term liabilities	14,946	13,019
COMMITMENTS (note 2)
STOCKHOLDERS' EQUITY:
Common stock, $0.012 par value (30,000,000 authorized shares; 13,319,172 and 13,183,425 shares issued and outstanding as of May 31, 2017 and August 31, 2016, respectively)	159	157
Additional paid-in capital	72,954	71,943
Accumulated other comprehensive income	497	106
Accumulated loss	(53,800)	(46,016)
Total stockholders' equity	19,810	26,190
Total liabilities and stockholders' equity	$ 39,792	$ 42,830

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	May 31, 2017	Aug. 31, 2016
Balance Sheets [Abstract]
Common stock, par value	$ 0.012	$ 0.012
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	13,319,172	13,183,425
Common stock, shares outstanding	13,319,172	13,183,425

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
Income Statement [Abstract]
REVENUES	$ (617)	$ (163)	$ (1,838)	$ (288)
COST OF REVENUES		8	187	12
RESEARCH AND DEVELOPMENT EXPENSES	2,267	1,710	7,745	4,914
GENERAL AND ADMINISTRATIVE EXPENSES	505	555	1,824	1,833
OPERATING LOSS	2,155	2,110	7,918	6,471
FINANCIAL INCOME	(210)	(137)	(599)	(330)
FINANCIAL EXPENSES	20	23	65	63
LOSS BEFORE TAXES ON INCOME	1,965	1,996	7,384	6,204
TAXES ON INCOME			400
NET LOSS FOR THE PERIOD	1,965	1,996	7,784	6,204
UNREALIZED LOSS (GAIN) ON AVAILABLE FOR SALE SECURITIES	(286)	(84)	(391)	244
TOTAL OTHER COMPREHENSIVE LOSS (INCOME)	(286)	(84)	(391)	244
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	$ 1,679	$ 1,912	$ 7,393	$ 6,448
LOSS PER SHARE OF COMMON STOCK:
BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK	$ 0.15	$ 0.15	$ 0.59	$ 0.50
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK	13,300,937	13,118,611	13,262,310	12,450,497

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - 9 months ended May 31, 2017 - USD ($)
$ in Thousands

Total

Common Stock

Additional paid-in capital

Accumulated other comprehensive income

Accumulated loss

BALANCE at Aug. 31, 2016

$ 26,190

$ 157

$ 71,943

$ 106

$ (46,016)

BALANCE, SHARES at Aug. 31, 2016

13,183

SHARES ISSUED FOR SERVICES

^[1]

SHARES ISSUED FOR SERVICES, SHARES

EXERCISE OF OPTIONS

320

$ 1

319

EXERCISE OF OPTIONS, SHARES

STOCK-BASED COMPENSATION

642

$ 1

641

STOCK-BASED COMPENSATION, SHARES

NET LOSS

7,784

(7,784)

OTHER COMPREHENSIVE INCOME

391

BALANCE at May. 31, 2017

$ 19,810

$ 159

$ 72,954

$ 497

$ (53,800)

BALANCE, SHARES at May. 31, 2017

13,319

[1]	Represents an amount of less than $1.

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	May 31, 2017	May 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ 7,784	$ 6,204
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	4	3
Exchange differences and interest on deposits and held to maturity bonds	(109)	(120)
Stock-based compensation	642	590
Shares issued for services	51	81
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	71	(294)
Accounts payable, accrued expenses and related parties	1,128	(301)
Deferred revenues	2,138	4,095
Liability for employee rights upon retirement	4	2
Other liabilities	72
Total net cash used in operating activities	(3,783)	(2,148)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(5)	(9)
Purchase of short-term deposits	(2,057)	(6,511)
Purchase of long-term deposits	(11,000)	(10,874)
Purchase of held to maturity securities	(2,904)	(1,775)
Proceeds from sale of short-term deposits	15,151	8,870
Proceeds from maturity of held to maturity securities	2,105	600
Funds in respect of employee rights upon retirement	(2)	(1)
Total net cash provided by (used in) investing activities	1,288	(9,700)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and vested restricted stock units net of issuance expenses		10,594
Proceeds from exercise of warrants and options	320	1,338
Total net cash provided by financing activities	320	11,932
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	1	5
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(2,174)	89
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	3,907	3,213
CASH AND CASH EQUIVALENTS AT END OF PERIOD	1,733	3,302
SUPPLEMENTARY DISCLOSURE ON CASH FLOWS -
Interest received	$ 564	$ 187

Significant Accounting Policies

9 Months Ended

May 31, 2017

Significant Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:

General:

Incorporation and operations

Oramed Pharmaceuticals Inc. (collectively with its subsidiary, the “Company”, unless the context indicates otherwise) was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd. (“Hadasit”) to acquire the provisional patent related to orally ingestible insulin capsule to be used for the treatment of individuals with diabetes.

On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the “Subsidiary”), which is engaged in research and development.

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

On November 30, 2015, the Company and its Israeli subsidiary entered into a Technology License Agreement with Hefei Tianhui Incubation of Technologies Co. Ltd. (“HTIT”) and on December 21, 2015, the parties entered into an Amended and Restated Technology License Agreement that was further amended by the parties on June 3, 2016 and July 24, 2016 (the “License Agreement”). According to the License Agreement, the Company granted HTIT an exclusive commercialization license in the territory of the People’s Republic of China, Macau and Hong Kong (the “Territory”), related to the Company’s oral insulin capsule, ORMD-0801 (the “Product”). Pursuant to the License Agreement, HTIT will conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to the Subsidiary’s technology and ORMD-0801 capsule, and will pay to the Subsidiary (i) royalties of 10% on net sales of the related commercialized products to be sold by HTIT in the Territory (“Royalties”), and (ii) an aggregate of $37,500, of which $3,000 was payable immediately, $8,000 will be paid subject to the Company entering into certain agreements with certain third parties, and $26,500 will be paid upon achievement of certain milestones and conditions. In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the final expiration of the Company’s patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certain circumstances, to 5%.

The royalty payment obligation shall apply during the period of time beginning upon the first commercial sale of the Product in the Territory, and ending upon the later of (i) the expiration of the last-to-expire licensed patents in the Territory; and (ii) 15 years after the first commercial sale of the Product in the Territory (the “Royalty Term”).

The License Agreement shall remain in effect until the expiration of the Royalty Term. The License Agreement contains customary termination provisions.

Among others, the Company’s involvement through the product submission date will include consultancy for the pre-commercialization activities in the Territory, as well as advisory services to HTIT on an ongoing basis.

The closing of the License Agreement was conditioned upon the approval of the Israel Innovation Authority of the Israeli Ministry of Economy & Industry (“IIA”), which was received on December 21, 2015.

The initial payment of $3,000 was received in January 2016 and the second and third payments of $6,500 and $4,000, respectively, were received in July 2016 following the achievement of certain milestones and the fourth milestone payment of $4,000 was received in October 2016.

In addition, on November 30, 2015, the Company entered into a Stock Purchase Agreement with HTIT (the “SPA”). According to the SPA, the Company issued 1,155,367 shares of common stock to HTIT for $12,000. The transaction closed on December 28, 2015.

The License Agreement and the SPA were considered a single arrangement with multiple deliverables. The Company allocated the total consideration of $49,500 between the License Agreement and the SPA according to their fair value, as follows: $10,617 was allocated to the issuance of common stock (less issuance expenses of $23), based on the quoted price of the Company’s shares on the closing date of the SPA on December 28, 2015, and $38,883 was allocated to the License Agreement. Given the Company’s continuing involvement through the expected product submission (June 2023), amounts received relating to the License Agreement are recognized over the period from which the Company is entitled to the respective payment, and the expected product submission date using a time-based model approach over the periods that the fees are earned.

In July 2015, according to the letter of intent signed between the parties or their affiliates, HTIT’s affiliate paid the Subsidiary a non-refundable amount of $500 as a no-shop fee. The no-shop fee was deferred and the related revenue is recognized over the estimated term of the License Agreement.

Amounts that were allocated to the License Agreement as of May 31, 2017 aggregated $19,383, all of which were received through the balance sheet date. Through May 31, 2017, the Company recognized revenue in the amount of $2,479, and deferred the remaining amount of $16,904.

Development and liquidity risks

The Company is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated significant revenues from its operations. Continued operation of the Company is contingent upon obtaining sufficient funding until it becomes profitable. Successful completion of the Company’s development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the U.S. Food and Drug Administration prior to selling its products within the United States, obtaining foreign regulatory approvals to sell its products internationally, or entering into licensing agreements with third parties. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company’s ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.

Loss per common share

Basic and diluted net loss per common share are computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding for each period. Outstanding stock options, warrants and restricted stock units (“RSUs”) have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The total number of common stock options, warrants and RSUs excluded from the calculation of diluted net loss was 1,874,786 and 2,740,656 for the nine month periods ended May 31, 2017 and 2016, respectively, and 1,523,869 and 2,584,518 for the three month periods ended May 31, 2017 and 2016, respectively, because the effect would be anti-dilutive.

Condensed Consolidated Financial Statements Preparation

The condensed consolidated financial statements included herein have been prepared in accordance with U.S. GAAP and on the same basis as the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended August 31, 2016 (the “2016 Form 10-K”). These condensed consolidated financial statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair statement of the results of the periods presented. Certain information and disclosures normally included in annual consolidated financial statements have been omitted in this interim period report pursuant to the rules and regulations of the Securities and Exchange Commission. Because the condensed consolidated interim financial statements do not include all of the information and disclosures required by U.S. GAAP for annual financial statements, they should be read in conjunction with the audited consolidated financial statements and notes included in the 2016 Form 10-K. The results for interim periods are not necessarily indicative of a full fiscal year’s results.

Newly issued and recently adopted Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue upon the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2017 (early adoption is permitted for the interim and annual periods beginning on or after December 15, 2016). The Company is currently evaluating the impact of the guidance on its consolidated financial statements.

Commitments

9 Months Ended

May 31, 2017

Commitments [Abstract]

COMMITMENTS

NOTE 2 - COMMITMENTS:

In March 2011, the Subsidiary sold shares of its investee company, Entera Bio Ltd. (“Entera”) to D.N.A Biomedical Solutions Ltd. (“D.N.A”), retaining a 3% interest as of March 2011, which is accounted for as a cost method investment (amounting to $1). In consideration for the shares sold to D.N.A, the Company received, among other payments, 4,202,334 ordinary shares of D.N.A (see also note 4).

As part of this agreement, the Subsidiary entered into a patent transfer agreement according to which, the Subsidiary assigned to Entera all of its right, title and interest in and to the patent application that it has licensed to Entera since August 2010. Under this agreement, the Subsidiary is entitled to receive from Entera royalties of 3% of Entera’s net revenues (as defined in the agreement) and a license back of that patent application for use in respect of diabetes and influenza. As of May 31, 2017, Entera had not yet realized any revenues and had not paid any royalties to the Subsidiary.

In addition, as part of a consulting agreement with a third party, dated February 15, 2011, the Subsidiary is obliged to pay this third party royalties of 8% of the net royalties received in respect of the patent that was sold to Entera in March 2011.

On January 3, 2017, the Subsidiary entered into a lease agreement for its office facilities in Israel. The lease agreement is for a period of 60 months commencing October 1, 2016.

The annual lease payment will be New Israeli Shekel (“NIS”) 119,000 ($33) from October 2016 through September 2018 and NIS 132,000 ($36) from October 2018 through September 2021, and will be linked to the increase in the Israeli consumer price index (“CPI”) (as of May 31, 2017, the future lease payments until the expiration of the lease agreement will be $156, based on the exchange rate as of May 31, 2017).

As security for its obligation under this lease agreement, the Company provided a bank guarantee in an amount equal to three monthly lease payments.

On March 3, 2016, the Subsidiary entered into an agreement for process development and production of its capsules and on November 24, 2016 and April 3, 2017 into amendments to such agreement with a vendor in an amount of up to Swiss Franc (“CHF”) 880,000 ($879), CHF 485,000 ($501) of which was recognized through May 31, 2017.

On May 11, 2016, the Subsidiary entered into a Master Service Agreement with a vendor to retain its services for a pre-clinical toxicology trial for an oral GLP-1 analog capsule for type 2 diabetes patients. As consideration for its services, the Subsidiary will pay the vendor a total amount of $1,200 during the term of the engagement and based on achievement of certain milestones, of which $1,163 was recognized through May 31, 2017.

On May 31, 2016, the Company entered into a consulting agreement with a third party advisor for a period of one year, pursuant to which such advisor will provide investor relations services and will be entitled to receive a monthly cash fee and 10,000 shares of the Company’s common stock that will be issued in four equal quarterly installments commencing August 1, 2016. As of May 31, 2017, the Company had issued to such advisor 10,000 shares. The fair value of the shares at the grant date was $72.

On May 3, 2017, the Company entered into a consulting agreement with the same third party advisor for a period of additional year, pursuant to which such advisor will provide investor relations services and will be entitled to receive a monthly cash fee and 10,000 shares of the Company’s common stock that will be issued in four equal quarterly installments commencing August 1, 2017. As of May 31, 2017, the Company had not issued to such advisor any shares in connection with this agreement.

On June 13, 2016, the Subsidiary entered into a four-year service agreement with a third party and on December 19, 2016, this agreement and all of the third party rights and obligations thereunder were assigned to another third party. This agreement is required by the License Agreement as described in note 1 and will support the Company’s research and development. The Subsidiary is obligated to pay the third party a total amount of up to €2,360,000 ($2,630), of which €800,000 ($892) is a non-refundable fee to be paid within 12 months from the effective date, and €550,000 ($597) of which was recognized in research and development through May 31, 2017. The remaining fee will be paid over the term of the engagement and will be based on achievement of certain milestones.

On March 3, 2014, the Subsidiary entered into a Master Service Agreement with a vendor for the process development and production of one of its oral capsule ingredients in the amount of $311, $175 of which was recognized through May 31, 2017, and bonus payments of up to $600 that will be paid upon achieving certain milestones, as described in the agreement, none of which was recognized through May 31, 2017.

On July 24, 2016, the Subsidiary entered into a General Technical Agreement with the same vendor, for the scale-up process development and production of the same capsule ingredients in the amount of $4,300 that will be paid over the term of the engagement and based on the achievement of certain development milestones, $3,263 of which were recognized in research and development through May 31, 2017. This agreement is part of the requirements of the License Agreement as described in note 1.

On September 21, 2016, the Subsidiary entered into a Clinical Research Organization Service Agreement with a third party to retain it as a Clinical Research Organization (“CRO”) for its Phase 2a dose finding clinical trial for an oral insulin capsule for type 2 diabetes patients, which began in the fourth quarter of calendar year 2016. As consideration for its services, the Subsidiary will pay the CRO a total amount of approximately $819 during the term of the engagement and based on achievement of certain milestones, all of which was recognized through May 31, 2017.

On February 21, 2017, the Subsidiary entered into an agreement with a vendor to retain its services for a pre-clinical toxicology trial for an oral insulin capsule for type 2 and type 1 diabetes patients. As consideration for its services, the Subsidiary will pay the vendor a total of up to $952 during the term of the engagement and based on achievement of certain milestones, of which $426 was recognized through May 31, 2017.

Grants from the Bio-Jerusalem Fund (“Bio-Jerusalem”)

The Subsidiary is committed to pay royalties to Bio-Jerusalem on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received (Israeli CPI linked) at the total amount of $65. The Company received no grants from Bio-Jerusalem since fiscal year 2013.

Royalty expenses for the nine month period ended May 31, 2017 of $47 are included in cost of revenues. As of May 31, 2017, the Subsidiary had realized revenues from its related project in the amount of $2,097.

Grants from the IIA

Under the terms of the Company’s funding from the IIA, royalties of 3.5% are payable on sales of products developed from a project so funded, up to a maximum amount equaling 100%-150% of the grants received (dollar linked) with the addition of interest at an annual rate based on LIBOR.

At the time the grants were received, successful development of the related projects was not assured.

The total amount that was received through May 31, 2017 was $2,194.

Royalty expenses for the nine month period ended May 31, 2017 of $140 are included in cost of revenues and will be paid over the term of the License Agreement in accordance with the revenue recognized from the related project. As of May 31, 2017, the Subsidiary had realized revenues from its project in the amount of $2,097.

Fair Value

9 Months Ended

May 31, 2017

Fair Value [Abstract]

FAIR VALUE

NOTE 3 - FAIR VALUE:

The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:

	Level 1:	Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

	Level 2:	Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

	Level 3:	Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

As of May 31, 2017, the assets or liabilities measured at fair value are comprised of available for sale equity securities (Level 1).

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.

As of May 31, 2017, the carrying amount of cash and cash equivalents, short-term deposits and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term maturities of these instruments.

As of May 31, 2017, the carrying amount of long-term deposits approximates their fair values due to the stated interest rates which approximate market rates.

The fair value of held to maturity bonds as presented in note 4 was based on a Level 1 measurement.

The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Marketable Securities

9 Months Ended

May 31, 2017

Marketable Securities [Abstract]

MARKETABLE SECURITIES

NOTE 4 - MARKETABLE SECURITIES:

The Company’s marketable securities include investments in equity securities of D.N.A and in held to maturity bonds.

Composition:

	May 31, 2017		August 31, 2016
Short-term:
D.N.A (see b below)	$	1,092	$	701
Held to maturity bonds (see c below)		1,980		2,154
	$	3,072	$	2,855
Long-term:
Held to maturity bonds (see c below)	$	1,409	$	530

D.N.A

The investment in D.N.A is reported at fair value, with unrealized gains and losses, recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities.

The D.N.A ordinary shares are traded on the Tel Aviv Stock Exchange and have a quoted price. The fair value of those securities is measured at the quoted prices of the securities on the measurement date.

As of May 31, 2017, the Company owns approximately 8.7% of D.N.A’s outstanding ordinary shares.

The cost of the securities as of each of May 31, 2017 and August 31, 2016 is $595.

Held to maturity securities

The amortized cost and estimated fair value of held-to-maturity securities at May 31, 2017, are as follows:

	May 31, 2017
	Amortized cost		Gross unrealized losses			Estimated fair value
Short-term:
Commercial bonds	$	1,951	$	(1	)	$	1,950
Accrued interest		29		-			29

Long-term		1,409		-			1,409
	$	3,389	$	(1	)	$	3,388

As of May 31, 2017, the contractual maturities of debt securities classified as held-to-maturity are as follows: after one year through two years, $1,409, and the yield to maturity rates vary between 1.40% to 2.05%.

The amortized cost and estimated fair value of held-to-maturity securities at August 31, 2016, are as follows:

	August 31, 2016
	Amortized cost		Gross unrealized gains		Estimated fair value
Short-term:
Commercial bonds	$	2,118	$	-	$	2,118
Accrued interest		36		-		36

Long-term		530		1		531
	$	2,684	$	1	$	2,685

As of August 31, 2016, the contractual maturities of debt securities classified as held-to-maturity are as follows: after one year through two years, $530 and the yield to maturity rates vary between 0.96% to 1.8%.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Stock-Based Compensation

9 Months Ended

May 31, 2017

Stock-Based Compensation [Abstract]

STOCK-BASED COMPENSATION

NOTE 5 - STOCK-BASED COMPENSATION

On November 1, 2016, the Company granted a total of 70,000 RSUs representing a right to receive 70,000 shares of the Company’s common stock to an employee of the Subsidiary. The RSUs vest in 19 installments, consisting of one installment of 9,000 shares on November 1, 2016, 18 equal monthly installments of 1,500 shares each, commencing November 30, 2016 and 17,000 shares on each of April 30, 2017 and 2018. The total fair value of these RSUs on the date of grant was $463, using the quoted closing market share price of $6.62 on the Nasdaq Capital Market on the date of grant. The Company elected to recognize compensation cost for this award using the accelerated method based on the multiple-option award approach.

On February 9, 2017, options to purchase an aggregate of 27,731 shares of the Company were granted to four members of the Company’s Board of Directors as follows: 16,337 options at an exercise price of $1 per share (lower than the traded market price on the date of grant) and 11,394 options at an exercise price of $6.23 per share (equivalent to the traded market price on the date of grant). The options vested immediately and expire on February 9, 2027. The fair value of all these options on the date of grant was $135, using the Black Scholes option-pricing model and was based on the following assumptions: Stock price of $6.23 dividend yield of 0% for all years; expected volatility of 77.29%; risk-free interest rates of 1.88%; and expected term of 5 years.

On March 20, 2017, options to purchase an aggregate of 37,152 of the Company’s shares of common stock were granted to a consultant at an exercise price of $6.00 per share (higher than the traded market price on the date of grant). The options expire on March 20, 2027. The options vest in 24 consecutive equal installments of 1,548 shares of common stock each, commencing March 31, 2017. The fair value of these options as of May 31, 2017 was $248, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 75.52%; risk-free interest rates of 2.21%; and expected term of 9.8 years.

On April 2, 2015, the Company entered into an At The Market Issuance Sales Agreement and on April 5, 2017 into an amendment to such agreement (as amended, the “Sales Agreement”) with FBR Capital Markets & Co. (“FBR”) pursuant to which the Company may, from time to time and at its option, issue and sell shares of its common stock having an aggregate offering price of up to $25,000 through FBR as its sales agent, subject to certain terms and conditions. Any shares sold will be sold pursuant to the Company’s effective shelf registration statement on Form S-3 including a prospectus dated February 2, 2017, as supplemented by a prospectus supplement dated April 5, 2017. The Company will pay FBR a commission of 3.0% of the gross proceeds of the sale of any shares sold through FBR. To date, no shares have been sold under the Sales Agreement.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Related Parties - Transactions	9 Months Ended
Related Parties - Transactions	May 31, 2017
Related Parties - Transactions [Abstract]
RELATED PARTIES - TRANSACTIONS	NOTE 6 - RELATED PARTIES - TRANSACTIONS On July 1, 2008, the Subsidiary entered into a consulting agreement with KNRY Ltd. (“KNRY”), an Israeli company owned by the Company’s Chief Executive Officer (“CEO”), whereby the CEO, through KNRY, provides services to the Company (the “Consulting Agreement”). The Consulting Agreement is terminable by either party upon 60 days written notice. The Consulting Agreement provides that KNRY (i) will be paid a gross amount of NIS 50,400 ($13) per month for the CEO and (ii) will be reimbursed for reasonable expenses incurred in connection with the performance of the Consulting Agreement. The Consulting Agreement has been amended several times. According to the latest amendment on November 28, 2016, the CEO’s monthly payment was set at NIS 127,570 ($33) effective January 2017, and an additional cost of $10 per year was approved for the use and maintenance of the CEO’s car effective November 2016.

Subsequent Event

9 Months Ended

May 31, 2017

Subsequent Event [Abstract]

SUBSEQUENT EVENT

NOTE 7 - SUBSEQUENT EVENT

On June 30, 2017, the Company granted options to purchase shares of the Company and RSU’s to its related parties as follows:

to the CEO, options to purchase an aggregate of 147,000 shares of the Company, at an exercise price of $7.77 per share (equivalent to the traded market price on the date of grant). The options shall vest in three equal annual installments of 49,000 each, on each of December 31, 2017, 2018 and 2019, subject to the Company share price reaching the target of $8.00 per share, $9.50 per share and $12.50 per share, respectively. These options expire on June 30, 2027.

To the Chief Scientific Officer, 75,000 RSUs representing a right to receive shares of the Company’s common stock which vested immediately, and options to purchase an aggregate of 69,999 shares of the Company, at an exercise price of $7.77 per share (equivalent to the traded market price on the date of grant). The options shall vest in three equal annual installments of 23,333 each, on each of December 31, 2017, 2018 and 2019. These options expire on June 30, 2027.

To four members of the Company’s Board of Directors, options to purchase an aggregate of 67,092 shares of the Company (16,773 options to each director), at an exercise price of $7.77 per share (equivalent to the traded market price on the date of grant). The options shall vest in three equal annual installments, on each of December 31, 2017, 2018 and 2019. These options expire on June 30, 2027.

To a member of the Company’s Board of Directors, options to purchase an aggregate of 56,773 shares of the Company at an exercise price of $7.77 per share (equivalent to the traded market price on the date of grant). The options shall vest in four annual installments, 15,591 shall vest on each of December 31, 2017, 2018 and 2019, and 10,000 shall vest on December 31, 2020. These options expire on June 30, 2027.

Significant Accounting Policies (Policies)

9 Months Ended

May 31, 2017

Significant Accounting Policies [Abstract]

General

General:

Incorporation and operations

On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the “Subsidiary”), which is engaged in research and development.

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

The License Agreement shall remain in effect until the expiration of the Royalty Term. The License Agreement contains customary termination provisions.

Development and liquidity risks

Loss per common share

Loss per common share

Condensed Consolidated Financial Statements Preparation

Condensed Consolidated Financial Statements Preparation

Newly issued and recently adopted Accounting Pronouncements

Newly issued and recently adopted Accounting Pronouncements

Marketable Securities (Tables)

9 Months Ended

May 31, 2017

Marketable Securities [Abstract]

Schedule of marketable securities include investments in equity securities

	May 31, 2017		August 31, 2016
Short-term:
D.N.A (see b below)	$	1,092	$	701
Held to maturity bonds (see c below)		1,980		2,154
	$	3,072	$	2,855
Long-term:
Held to maturity bonds (see c below)	$	1,409	$	530

Schedule of amortized cost and estimated fair value of held-to-maturity securities

	May 31, 2017
	Amortized cost		Gross unrealized losses			Estimated fair value
Short-term:
Commercial bonds	$	1,951	$	(1	)	$	1,950
Accrued interest		29		-			29

Long-term		1,409		-			1,409
	$	3,389	$	(1	)	$	3,388

	August 31, 2016
	Amortized cost		Gross unrealized gains		Estimated fair value
Short-term:
Commercial bonds	$	2,118	$	-	$	2,118
Accrued interest		36		-		36

Long-term		530		1		531
	$	2,684	$	1	$	2,685

- Definition

Tabular disclosure of all investments in certain debt and equity securities for which the entity has the positive intent and ability to hold until maturity.

+ References + Details

Significant Accounting Policies (Details) - USD ($) $ in Thousands						3 Months Ended		9 Months Ended
	Oct. 31, 2016	Jul. 31, 2016	Jan. 31, 2016	Dec. 28, 2015	Nov. 30, 2015	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016	Jul. 31, 2015
Significant Accounting Policies (Textual)
License payment received			$ 3,000
Number of common stock issued ,value				$ 49,500
DIluted net loss						1,523,869	2,584,518	1,874,786	2,740,656
Stock Purchase Agreement [Member]
Significant Accounting Policies (Textual)
Number of common stock issued ,value				10,617
Issuance expenses				23
License Agreement [Member]
Significant Accounting Policies (Textual)
Aggregate license costs								$ 19,383
Number of common stock issued ,value				$ 38,883
Recognize revenue								2,479
Deferred costs						$ 16,904		$ 16,904
Second Milestone [Member]
Significant Accounting Policies (Textual)
License payment received		$ 6,500
Third Milestone [Member]
Significant Accounting Policies (Textual)
License payment received		$ 4,000
Forth milestone [Member]
Significant Accounting Policies (Textual)
License payment received	$ 4,000
HTIT [Member]
Significant Accounting Policies (Textual)
Percentages of royalties on net sales								10.00%
Aggregate license costs								$ 37,500
License costs payable						3,000		3,000
Amount paid subject to the company entering into certain agreements						8,000		8,000
Payable upon achievement of certain milestones and conditions						$ 26,500		$ 26,500
Royalty commitment description								<div>In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the final expiration of the Company’s patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certain circumstances, to 5%.</div>
Non-refundable amount										$ 500
Royalty term							15 Years
HTIT [Member] \| Stock Purchase Agreement [Member]
Significant Accounting Policies (Textual)
Number of common stock issued					1,155,367
Number of common stock issued ,value					$ 12,000

Commitments (Details) € in Thousands, ₪ in Thousands, SFr in Thousands, $ in Thousands								1 Months Ended				3 Months Ended		9 Months Ended
	Oct. 31, 2016	Jun. 13, 2016 USD ($)	Jun. 13, 2016 EUR (€)	May 11, 2016 USD ($)	Mar. 03, 2016 USD ($)	Mar. 03, 2016 CHF (SFr)	Mar. 03, 2014 USD ($)	Feb. 21, 2017 USD ($)	Sep. 21, 2016 USD ($)	Jul. 24, 2016 USD ($)	Mar. 31, 2011 USD ($) shares	May 31, 2017 USD ($)	May 31, 2016 USD ($) shares	May 31, 2017 USD ($) shares	May 31, 2017 EUR (€) shares	May 31, 2017 CHF (SFr) shares	May 31, 2016 USD ($) shares	May 31, 2017 ILS (₪)	May 03, 2017 shares	Feb. 15, 2011
Commitments (Textual)
Stock issued for services during the period, fair value														$ 51			$ 81
Research and development												$ (2,267)	$ (1,710)	(7,745)			(4,914)
Revenues												(617)	$ (163)	(1,838)			$ (288)
Office Building [Member]
Commitments (Textual)
Annual lease payments from October 2016 through September 2018												33		33				₪ 119
Operating lease term	60 months
Annual lease payments from October 2018 through September 2021												36		36				₪ 132
Future minimum lease payments												$ 156		156
Bio-Jerusalem Fund [Member]
Commitments (Textual)
Royalty expenses														47
Grants received														65
Revenues														$ 2,097
Bio-Jerusalem Fund [Member] \| Minimum [Member]
Commitments (Textual)
Royalty percentage												4.00%		4.00%				4.00%
Bio-Jerusalem Fund [Member] \| Maximum [Member]
Commitments (Textual)
Royalty percentage												100.00%		100.00%				100.00%
Israel Innovation Authority [Member]
Commitments (Textual)
Royalty percentage												3.50%		3.50%				3.50%
Royalty expenses														$ 140
Grants received														2,194
Revenues														$ 2,097
Israel Innovation Authority [Member] \| Minimum [Member]
Commitments (Textual)
Royalty percentage												100.00%		100.00%				100.00%
Israel Innovation Authority [Member] \| Maximum [Member]
Commitments (Textual)
Royalty percentage												150.00%		150.00%				150.00%
Entera Bio Ltd [Member] \| D.N.A.Biomedical Solutions Ltd [Member]
Commitments (Textual)
Ownership percentage retained											3.00%
Ordinary shares received \| shares											4,202,334
Cost method investment											$ 1
Royalty percentage											3.00%									8.00%
Advisor [Member]
Commitments (Textual)
Shares issued for services \| shares														10,000	10,000	10,000
Stock issuable for services, shares \| shares													10,000				10,000		10,000
Stock issued for services during the period, fair value														$ 72
Clinical Research Organization Service Agreement [Member]
Commitments (Textual)
Commitments for consulting services									$ 819
Master Service Agreement [Member]
Commitments (Textual)
Commitments for consulting services		$ 2,630	€ 2,360	$ 1,200			$ 311
Service fee recognised							$ 175							1,163
Commitments for bonus payments upon achieving certain milestones														600
Non-refundable amount		$ 892	€ 800
Research and development														597	€ 550
Proposal Agreement [Member]
Commitments (Textual)
Development and production on capsules					$ 879	SFr 880								501		SFr 485
General Technical Agreement [Member]
Commitments (Textual)
Commitments for consulting services										$ 4,300
Research and development														3,263
Pre-clinical Toxicology Trial [Member]
Commitments (Textual)
Commitments for consulting services								$ 952
Research and development														$ 426

Marketable Securities (Details) - USD ($) $ in Thousands	May 31, 2017	Aug. 31, 2016
Short-term:
D.N.A (see b below)	$ 1,092	$ 701
Held to maturity bonds (see c below)	1,980	2,154
Marketable securities	3,072	2,855
Long-term:
Held to maturity bonds (see c below)	$ 1,409	$ 530

Marketable Securities (Details 1) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
Marketable Securities (Details 1) - USD ($) $ in Thousands	May 31, 2017	Aug. 31, 2016
Net Investment Income [Line Items]
Amortized cost	$ 3,389	$ 2,684
Gross unrealized losses	(1)	1
Estimated fair value	3,388	2,685
Long-term [Member]
Net Investment Income [Line Items]
Amortized cost	1,409	530
Gross unrealized losses		1
Estimated fair value	1,409	531
Commercial bonds [Member] \| Short-term: [Member]
Net Investment Income [Line Items]
Amortized cost	1,951	2,118
Gross unrealized losses	(1)
Estimated fair value	1,950	2,118
Accrued interest [Member] \| Short-term: [Member]
Net Investment Income [Line Items]
Amortized cost	29	36
Gross unrealized losses
Estimated fair value	$ 29	$ 36

Marketable Securities (Details Textual) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	May 31, 2017	Aug. 31, 2016
Marketable Securities (Textual)
Percentage of ownership interest	8.70%
Cost of securities	$ 595	$ 595
Marketable securities	$ 1,409	$ 530
Minimum [Member]
Marketable Securities (Textual)
Yield to cost rates	1.40%	0.96%
Maximum [Member]
Marketable Securities (Textual)
Yield to cost rates	2.05%	1.80%

Stock-Based Compensation (Details) $ / shares in Units, $ in Thousands				1 Months Ended					9 Months Ended
	Feb. 09, 2017 USD ($) $ / shares shares	Nov. 01, 2016 USD ($) Installments $ / shares shares	Apr. 02, 2015	Jun. 30, 2017 Installments $ / shares shares	Apr. 30, 2017 shares	Mar. 31, 2017 Installments shares	Mar. 20, 2017 $ / shares shares	Nov. 30, 2016 Installments shares	May 31, 2017 USD ($) shares	Apr. 05, 2015 USD ($)
Stock-Based Compensation (Textual)
Options vested						1,548
Stock options granted	11,394
Stock options exercise price \| $ / shares	$ 6.23
Consultant [Member]
Stock-Based Compensation (Textual)
Number of installments \| Installments						24
Stock options granted							37,152
Stock options exercise price \| $ / shares							$ 6.00
Expiration date							Mar. 20, 2027
Fair value of options \| $									$ 248
Dividend yield									0.00%
Expected volatility									75.52%
Risk-free interest rates									2.21%
Expected term									9 years 9 months 18 days
FBR [Member]
Stock-Based Compensation (Textual)
Common stock aggregate offering price \| $										$ 25,000
Percentage of commission paid			3.00%
Options [Member]
Stock-Based Compensation (Textual)
Stock options granted	27,731
Stock options exercise price \| $ / shares	$ 6.23
Expiration date	Feb. 09, 2027
Fair value of options \| $	$ 135
Dividend yield	0.00%
Expected volatility	77.29%
Risk-free interest rates	1.88%
Expected term	5 years
Board of Directors [Member]
Stock-Based Compensation (Textual)
Stock options granted	16,337
Stock options exercise price \| $ / shares	$ 1
Employee [Member]
Stock-Based Compensation (Textual)
Number of common stock issued		70,000
Subsequent event [Member] \| Board of Directors [Member]
Stock-Based Compensation (Textual)
Number of installments \| Installments				3
Stock options granted				67,092
Stock options exercise price \| $ / shares				$ 7.77
Expiration date				Jun. 30, 2027
Restricted stock units [Member]
Stock-Based Compensation (Textual)
Number of shares reserved for grant		70,000
Number of installments \| Installments		19
Options vested					17,000
Fair value of restricted stock units \| $		$ 463
Quoted closing market share price \| $ / shares		$ 6.62
Restricted stock units [Member] \| 2018 [Member]
Stock-Based Compensation (Textual)
Options vested									17,000
Restricted stock units [Member] \| One installment [Member]
Stock-Based Compensation (Textual)
Number of installments \| Installments		1
Options vested		9,000
Restricted stock units [Member] \| 18 equal monthly installments [Member]
Stock-Based Compensation (Textual)
Number of installments \| Installments								18
Options vested								1,500

Related Parties - Transactions (Details) ₪ in Thousands, $ in Thousands	Jul. 01, 2008	Nov. 28, 2016 USD ($)	Nov. 28, 2016 ILS (₪)
KNRY [Member]
Related Parties Transactions (Textual)
Consulting agreements, description	The Consulting Agreement is terminable by either party upon 60 days written notice. The Consulting Agreement provides that KNRY (i) will be paid a gross amount of NIS 50,400 ($13) per month for the CEO and (ii) will be reimbursed for reasonable expenses incurred in connection with the performance of the Consulting Agreement.
CEO [Member]
Related Parties Transactions (Textual)
Monthly payment under consulting agreements		$ 33	₪ 127,570
Additional cost		$ 10

Subsequent Event (Details)		1 Months Ended
Subsequent Event (Details)	Feb. 09, 2017 $ / shares shares	Jun. 30, 2017 Installments $ / shares shares	Mar. 31, 2017 shares
Subsequent Event [Textual]
Stock options granted	11,394
Exercise price \| $ / shares	$ 6.23
Number of options vest per installment			1,548
Director [Member]
Subsequent Event [Textual]
Stock options granted	16,337
Exercise price \| $ / shares	$ 1
Subsequent event [Member] \| CEO [Member]
Subsequent Event [Textual]
Stock options granted		147,000
Exercise price \| $ / shares		$ 7.77
Expiration date		Jun. 30, 2027
Number of installments \| Installments		3
Subsequent event [Member] \| CEO [Member] \| 2017 [Member]
Subsequent Event [Textual]
Number of options vest per installment		49,000
Share price \| $ / shares		$ 8.00
Subsequent event [Member] \| CEO [Member] \| 2018 [Member]
Subsequent Event [Textual]
Number of options vest per installment		49,000
Share price \| $ / shares		$ 9.50
Subsequent event [Member] \| CEO [Member] \| 2019 [Member]
Subsequent Event [Textual]
Number of options vest per installment		49,000
Share price \| $ / shares		$ 12.50
Subsequent event [Member] \| Chief Scientific Officer [Member]
Subsequent Event [Textual]
Stock options granted		69,999
Exercise price \| $ / shares		$ 7.77
Expiration date		Jun. 30, 2027
Number of installments \| Installments		3
Number of options vest per installment		75,000
Subsequent event [Member] \| Chief Scientific Officer [Member] \| 2017 [Member]
Subsequent Event [Textual]
Number of options vest per installment		23,333
Subsequent event [Member] \| Chief Scientific Officer [Member] \| 2018 [Member]
Subsequent Event [Textual]
Number of options vest per installment		23,333
Subsequent event [Member] \| Chief Scientific Officer [Member] \| 2019 [Member]
Subsequent Event [Textual]
Number of options vest per installment		23,333
Subsequent event [Member] \| Director [Member]
Subsequent Event [Textual]
Stock options granted		67,092
Exercise price \| $ / shares		$ 7.77
Expiration date		Jun. 30, 2027
Number of installments \| Installments		3
Subsequent event [Member] \| Director one [Member]
Subsequent Event [Textual]
Stock options granted		16,773
Subsequent event [Member] \| Director two [Member]
Subsequent Event [Textual]
Stock options granted		16,773
Subsequent event [Member] \| Director three [Member]
Subsequent Event [Textual]
Stock options granted		16,773
Subsequent event [Member] \| Director four [Member]
Subsequent Event [Textual]
Stock options granted		16,773
Subsequent event [Member] \| Director five [Member]
Subsequent Event [Textual]
Stock options granted		56,773
Exercise price \| $ / shares		$ 7.77
Expiration date		Jun. 30, 2027
Number of installments \| Installments		4
Subsequent event [Member] \| Director five [Member] \| 2017 [Member]
Subsequent Event [Textual]
Number of options vest per installment		15,591
Subsequent event [Member] \| Director five [Member] \| 2018 [Member]
Subsequent Event [Textual]
Number of options vest per installment		15,591
Subsequent event [Member] \| Director five [Member] \| 2019 [Member]
Subsequent Event [Textual]
Number of options vest per installment		15,591
Subsequent event [Member] \| Director five [Member] \| 2020 [Member]
Subsequent Event [Textual]
Number of options vest per installment		10,000